secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0000885725-25-000046
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q3 sales $5.065B (+20.3% reported) beat guidance; adjusted EPS $0.75 beats $0.70-0.72
--------------------------------------------------------------------------------

- GAAP net income $755M ($0.51 EPS) vs $469M ($0.32) a year ago; adjusted EPS $0.75 vs $0.63.
- Cardiovascular sales $3.343B (+22.4% reported); MedSurg $1.722B (+16.4%).
- U.S. sales +27.0% reported; EMEA +2.6% reported but -2.0% operational due to ACURATE discontinuation.
- FY2025 guidance: reported sales growth ~20%, organic ~15.5%; GAAP EPS $1.97-2.01, adjusted EPS $3.02-3.04.
- Agreed to acquire Nalu Medical (neuromodulation) and acquired Elutia's antibiotic-eluting Envelope products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/0000885725-25-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572525000046/bsx-20251022.htm
  HTML page:      https://secwatch.observer/filing/0000885725-25-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer